Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Loncastuximab Tesirine→

Loncastuximab Tesirine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1879918-31-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
CD19-directed antibody-drug conjugate (ADC)pyrrolobenzodiazepine (PBD) alkylating antineoplastic
Mechanism of action
The anti-CD19 IgG1 antibody binds CD19 on B-lineage cells and is internalised. Proteolytic cleavage releases the SG3199 PBD dimer payload, which binds the DNA minor groove and forms interstrand crosslinks, leading to cell death.
Indications / reported uses
  • Treatment of adults with relapsed or refractory large B-cell lymphoma after at least two prior systemic treatment lines, under the current product label.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af54af12-3edf-4301-8bc5-0446bc813c1d · https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761196s013lbl.pdf

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Loncastuximab Tesirine Environmental Risk Assessment (ERA) (the Loncastuximab Tesirine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.